Despite the overall failure of benralizumab to impress in patients with moderate to severe COPD, it may be possible to identify a subpopulation of responders using a combination of elevated blood eosinophils and clinical characteristics. Professor Gerard Criner, from Philadelphia’s Temple University, told the 2019 ERS Congress that the IL-5 receptor antagonist did not reduce ...
Predicting responses to benralizumab
By Mardi Chapman
15 Oct 2019